Company Profile
Gossamer Bio Stock Price, News & Catalysts
- Ticker:
- GOSS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.17 USD (+13.12%)
Close
Last updated: August 24, 2026
47M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, GOSS closed up 13.1% at $0.1750. No new same-company headline was identified in the current news window.
Company overview
Business overview
Gossamer Bio is a biotechnology company focused on pulmonary and inflammatory disease. Its programs aim to address serious conditions in areas where targeted therapies can matter.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Gossamer sits in specialty biotechnology.
Business Model Characteristics
The company depends on clinical data, target validation, and the ability to build a focused respiratory and inflammation franchise.
Position Within the Biotechnology Landscape
Gossamer is a catalyst-sensitive specialty name whose stock reacts to data, strategy, and execution.
Future catalysts
- Gossamer’s catalysts are seralutinib and the pulmonary-hypertension program, with the next update deciding whether the inhaled therapy can still build momentum. The company needs clean clinical progress to keep the story moving.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Gossamer Bio (GOSS)?
Gossamer Bio (GOSS) most recently closed at 0.17 USD, a +13.12% move versus the previous session.
What is the market cap of Gossamer Bio (GOSS)?
Gossamer Bio currently has a market capitalization of 47M USD on BioPharmSignal.
What does Gossamer Bio do?
Gossamer Bio is a biotechnology company focused on pulmonary and inflammatory disease. Its programs aim to address serious conditions in areas where targeted therapies can matter.
On which exchange is GOSS stock listed?
Gossamer Bio (GOSS) is associated with NASDAQ, United States, Biopharma.
What is seralutinib?
Gossamer’s catalysts are seralutinib and the pulmonary-hypertension program, with the next update deciding whether the inhaled therapy can still build momentum.
Which conditions is Gossamer Bio targeting with seralutinib?
Gossamer’s catalysts are seralutinib and the pulmonary-hypertension program, with the next update deciding whether the inhaled therapy can still build momentum.
How does Gossamer Bio describe recent progress with seralutinib?
Gossamer’s catalysts are seralutinib and the pulmonary-hypertension program, with the next update deciding whether the inhaled therapy can still build momentum.
What is Gossamer?
Gossamer Bio is a biotechnology company focused on pulmonary and inflammatory disease.